Pricing Log in Create free account
Friday 6 November 2026 Export ATEC’s income statement to Excel — free account

Alphatec Holdings, Inc.

ATEC Healthcare Medical Devices

Alphatec Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $764.2 million, up 25.0% from fiscal 2024.

Revenue
+12.6%
EPS
+84.2%
Free cash flow
−149.2%
Total debt
−2.27%

Quarter to September 2026, against a year earlier

7.49 0.31 −3.97%
Market cap
$1.2B
P/E
0.0×
Fwd P/E
−15.0×
Dividend yield
—
F-score
6/9
Altman Z
0.89
Beneish M
−3.43
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Bought, $m 2.42
Sold, $m 41.39
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — 1 — — — 1 1 —
Sell 12 1 2 5 — — 1 — 1 — — —
Insider Ownership 22.91%

Capital & Financial Ratios $m

Size
Market Cap 1,210.00
Revenue ttm 839.72
Net income ttm (86.89)
Free cash flow ttm (10.44)
Net debt Q 467.06
Valuation
P/E 0.00
Forward P/E (15.00) (negative: loss-making)
Price / sales 1.46
Forward P/S Powerpack
Price / FCF 0.00
Price / book 0.00
Financial health
Current ratio Q 2.36 (at or above 1.5: strong)
Debt / equity Q (237.62) (negative: negative equity)
Interest coverage Q 0.31
Growth
Revenue growth Q +12.55% (above 0%: growing)
Operating income growth Q +120.37% (above 0%: growing)
EPS, this year +488.32% (at or above 15%: strong)
EPS, next year A +91.50% (at or above 15%: strong)
Revenue, next year A +13.45% (at or above 10%: strong)
EPS, past 5 yrs —
EPS, next 5 yrs A +152.68% (at or above 15%: strong)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 2.0×, against a ten-year median of 2.9×; over the ten years it ranged from 0.3× in 2017 to 7.9× in 2021.
P/S against its own 10 years 31.83%
10-year low 10-year high
EV/Sales against its own 10 years 31.57%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 221 139 161 80
Receivables 73 83 97 111
Inventory 137 175 169 207
Other — — — —
451 417 451 427
2023 2024 2025 Q'26
Payables 49 53 41 62
ST’ Debt 2 2 — 5
Other 14 10 10 12
158 153 219 181

Compound Annual Growth %

10y 5y 3y
Sales 18.98% 39.46% 29.62%
Cash Flow 16.15% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 0.00% (37.46%) 0.00%

Earnings Trends EPS, adjusted, against the consensus

Q3 FY26 Estimate 0.11 Actual 0.09

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q4 FY25 0.04 0.06 Beat by 0.02
Q1 FY26 −0.01 0.00 Beat by 0.01
Q2 FY26 0.09 0.07 Miss by 0.02
Q3 FY26 0.11 0.09 Miss by 0.02
Q4 FY26 0.18 — Reports 23 February 2027

EPS $

Mar Jun Sep Dec Year
’26 (0.22) (0.16) (0.03) — —
’25 (0.35) (0.27) (0.19) (0.14) (0.96)
’24 (0.34) (0.29) (0.28) (0.23) (1.13)
’23 (0.40) (0.43) (0.35) (0.37) (1.54)
’22 (0.43) (0.36) (0.35) (0.33) (1.47)
’21 (0.26) (0.39) (0.43) (0.40) (1.50)
’20 (0.33) (0.25) (0.24) (0.35) (1.18)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 192 214 221 — —
’25 169 186 197 213 764
’24 138 146 151 177 612
’23 109 117 118 138 482
’22 71 84 90 106 351
’21 44 62 63 74 243
’20 30 30 41 44 145
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 1 21 19 — —
’25 (5) 16 14 21 45
’24 (38) (11) (5) 11 (45)
’23 (18) (18) (17) (25) (78)
’22 (25) (27) (15) (8) (75)
’21 (19) (17) (23) (15) (73)
’20 (17) (13) (10) (7) (46)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (13) (2) (2) — —
’25 (17) 3 3 6 (4)
’24 (72) (47) (25) 7 (138)
’23 (35) (38) (39) (53) (165)
’22 (38) (42) (30) (23) (133)
’21 (34) (37) (36) (34) (142)
’20 (20) (17) (15) (18) (70)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.3
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Sep ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 120 102 92 113 145 243 351 482 612 764 840 +22.8% 867 989 1,141 +14.3%
Gross margin, % 63.31 67.06 68.97 68.41 70.76 64.87 66.42 61.36 66.72 67.63 69.46 +4.3 pt
EBT (31) (5) (30) (57) (79) (144) (152) (187) (162) (143) (89) +18.6%
EBT margin, % (25.73) (4.50) (32.90) (50.38) (54.43) (59.27) (43.32) (38.76) (26.50) (18.77) (10.56) +7.0 pt
Net income (30) (2) (29) (57) (79) (143) (151) (187) (162) (143) (87) +19.0%
Per share, $
Per share, $ Revenue 14.01 7.96 2.60 2.17 2.16 2.53 3.39 3.98 4.28 5.09 5.34 (10.6%)
Earnings (3.57) (0.18) (1.20) (1.09) (1.18) (1.50) (1.47) (1.54) (1.13) (0.96) (0.55) (13.6%)
Cash flow (1.16) (0.68) (0.73) (0.63) (0.69) (0.76) (0.73) (0.65) (0.31) 0.30 0.39 n/m
Capex (0.91) (0.51) (0.17) (0.25) (0.36) (0.71) (0.56) (0.72) (0.65) (0.33) (0.46) (10.7%)
Free cash flow (2.07) (1.19) (0.90) (0.88) (1.05) (1.47) (1.29) (1.36) (0.96) (0.03) (0.07) (37.7%)
Book value (4.84) (2.08) 0.50 0.84 1.94 0.83 (0.34) 0.64 (0.10) 0.08 (0.01) n/m
Shares, m 9 13 35 52 67 96 103 121 143 150 155 +37.4%
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0
P/S 0.23 0.34 0.88 3.27 6.72 4.52 3.49 3.73 2.15 4.13 1.46 2.9
P/B 0.00 0.00 4.60 8.50 7.49 13.84 0.00 23.05 0.00 254.09 0.00 31.2
EV/Sales 0.45 0.52 1.06 3.33 6.27 5.11 4.30 4.34 2.86 4.66 2.02 3.3
EV/FCF (2.97) (3.30) (2.99) (8.05) (12.84) (8.70) (11.30) (12.65) (12.70) (807.82) (162.20) (88.3)
Cash, $m
Cash, $m Operating cash flow (10) (9) (26) (33) (46) (73) (75) (78) (45) 45 61 n/m
Capex (8) (6) (6) (13) (24) (69) (58) (87) (93) (50) (72) +22.8%
Free cash flow (18) (15) (32) (46) (70) (142) (133) (165) (138) (4) (10) (14.4%)
Balance, $m
Balance, $m Working capital 33 37 45 72 126 230 117 294 264 232 246 +24.3%
Net debt 27 19 17 7 (65) 144 285 292 437 341 467 +32.7%
Shareholders’ equity (42) (27) 18 44 130 79 (35) 78 (14) 12 (2) n/m
Returns, %
Returns, % ROA (24.88) (2.57) (39.66) (38.07) (36.64) (34.33) (27.68) (28.15) (20.51) (18.30) (10.97) +6.6 pt
ROIC 0.00 0.00 (41.14) (58.56) (56.43) (35.86) (36.75) (29.29) (20.11) (14.54) (4.04) (14.5) pt
ROE 76.65 6.73 934.91 (186.27) (91.05) (136.68) (676.09) (859.11) (507.05) 16,450.51 (1,888.01) +16,373.9 pt
People
People Employees 162 138 195 227 296 561 705 839 867 913 — +21.2%
Revenue/emp, $m 0.74 0.74 0.47 0.50 0.49 0.43 0.50 0.57 0.71 0.84 — +1.3%
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 5 Nov 2026

Alphatec Holdings, Inc. vs peers in Medical Devices (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
ENOV Enovis Corporation $1.7B — (loss-making) 98.6× +1.79% (above 0%: growing) n/m +20.30% (above 0%: growing) 60.83% 0.60% Compare
LMRI Lumexa Imaging Holdings, Inc. $1.3B — (loss-making) 38.0× +7.82% (above 0%: growing) n/m +257.54% (above 0%: growing) 14.72% 8.72% Compare
TNDM Tandem Diabetes Care, Inc. $1.3B — (loss-making) — (loss-making) +13.82% (above 0%: growing) n/m −231.98% (below 0%: shrinking) 56.55% (0.84%) Compare
AORT Artivion, Inc. $1.2B — (loss-making) — (loss-making) +11.32% (above 0%: growing) n/m −202.47% (below 0%: shrinking) 64.03% (6.65%) Compare
ATEC Alphatec Holdings, Inc. $1.2B — (loss-making) — (loss-making) +12.55% (above 0%: growing) n/m −149.22% (below 0%: shrinking) 71.55% 1.47%
PRCT PROCEPT BioRobotics Corporation $1.2B — (loss-making) — (loss-making) +17.96% (above 0%: growing) n/m −1.57% (below 0%: shrinking) 66.28% (27.85%) Compare
IART Integra LifeSciences Holdings Corporation $1.1B 83.0× 26.0× +2.27% (above 0%: growing) n/m +232.94% (above 0%: growing) 51.04% 4.60% Compare
IRMD iRadimed Corporation $1.1B 44.9× 39.6× +14.15% (above 0%: growing) +15.91% (above 0%: growing) +18.58% (above 0%: growing) 76.26% 33.63% Compare
SIBN SiBone $1.1B — (loss-making) — (loss-making) +14.49% (above 0%: growing) n/m +31.13% (above 0%: growing) 79.29% (7.81%) Compare
Median of peers $1.2B — 38.8× +12.57% — +19.44% 62.43% (0.12%)

All 149 Medical Devices stocks →

Pay and ownership Proxy statement filed 29 April 2026

Chief executive’s pay

Year Total pay Actually paid $100 invested
2025 10.26m 29.73m 191.90
2024 6.22m 4.06m 24.74
2023 9.48m 23.34m 108.32
2022 5.95m 7.37m 69.42
2021 5.27m 8.27m 56.45

Ownership

Directors and executive officers, together 13.48%
David R. Pelizzon 6.98%
Squadron Capital LLC Squadron Capital Holdings LLC Jennifer N. Pritzker David R. Pelizzon 6.76%
BlackRock, Inc. 5.01%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Alphatec Holdings, Inc. (ATEC) Latest News

30 Oct

Impact 3 · · Simply Wall St.
Impact 3 · · The Motley Fool transcript
Impact 3 · · TIKR
Impact 3 · · Moby

29 Oct

Impact 4 · · MarketBeat transcript
Impact 4 · · Associated Press
Impact 3 · · Zacks
Impact 3 · · Business Wire

27 Oct

Impact 4 · · Insider Monkey

18 Oct

Impact 4 · · Simply Wall St.

30 Sep

Impact 3 · · The Motley Fool

23 Sep

Impact 4 · · Business Wire

11 Aug

Impact 4 · · The Motley Fool transcript

7 Aug

Impact 3 ·

5 Aug

Impact 4 ·
Impact 3 · · Moby transcript

4 Aug

Impact 3 · · MarketBeat transcript
Impact 3 ·

12 May

Impact 3 · · Insider Monkey

7 May

Impact 3 · · Simply Wall St.

5 May

Impact 4 · · Moby
Impact 4 · · The Motley Fool transcript
Impact 4 · · Business Wire
Impact 3 · · The Motley Fool
Impact 3 · · MarketBeat
Impact 3 · · Zacks
Impact 3 · · Business Wire

23 Mar

Impact 3 ·

21 Mar

Impact 3 · · Insider Monkey

12 Mar

Impact 4 · · MarketBeat
stockrow.com/ATEC · Data as of Nov 5, 2026 · For information only; not investment advice. · © 2026 stockrow.com